Why Europe's HealthTech Mid-Market Is Where Private Equity Returns Are Being Made in 2026: The €25M to €250M Sweet Spot

Average HealthTech deal size has more than tripled since 2022, but the entry multiples that make a fund's vintage are still found below €250M EV.
  
Global and European healthcare M&A surged in 2025, with global transaction value reaching $546.7 billion, a 38% increase year-over-year. In Europe, private equity healthcare buyout value reached $80.9 billion in 2025 and is projected to surpass $95.0 billion in 2026. Disclosed global healthcare buyout value exceeded $191 billion in 2025, propelled by pent-up capital deployment and large platform transactions exceeding $1 billion in Enterprise Value (EV). 
  
However, headline deployment numbers mask a bifurcated market. In the mega-cap space, intense competition among bulge-bracket sponsors and strategic acquirers has driven entry multiples to 15x–25x EBITDA. At these valuations, achieving hurdle rates requires aggressive leverage and near-flawless operational execution.

Genuine alpha and upper-quartile Multiple on Invested Capital (MOIC) are concentrated in the lower-to-middle market (LMM): European targets valued between €25 million and €250 million EV, generating €1 million to €10 million in operating EBITDA. 
  
These founder-led businesses trade at entry multiples of 10x–14x EBITDA, offering institutional sponsors insulation from competitive public auctions, structural inefficiency in target advisory, and an abundant supply of high-margin assets ready for buy-and-build expansion.

Strategic Execution Framework
  
The 2026 European healthcare private equity market presents a clear strategic choice: while mega-cap platform valuations remain crowded and fully priced, lower mid-market HealthTech targets (€25M–€250M EV) offer an attractive risk-adjusted risk/return profile. 

Sourcing founder-led assets generating €1M to €10M in EBITDA allows sponsors to deploy capital at reasonable entry multiples while capturing structured, multi-turn valuation expansion.
  
To systematically generate alpha in this market segment, private equity sponsors should execute a four-part strategy:
  
Target High Regulatory Moats: Allocate capital to AI-native clinical tools ("glass box" architectures), EHDS data interoperability infrastructure, and MDR-certified clinical hardware where regulatory compliance establishes sustainable competitive barriers.

Exploit the Advisory Gap: Build direct sourcing networks and leverage specialized regulatory advisors to identify underbanked, founder-led targets across fragmented European markets before they enter broad sell-side auctions.

Drive Buy-and-Build Multiple Arbitrage: Acquire core regional platforms at 10x–12x EBITDA and execute strategic add-on acquisitions at lower multiples to aggregate EBITDA past the institutional €10M threshold.

Underwrite Profit-Weighted Growth: Transition portfolio companies from top-line growth metrics toward balanced Rule of 40 performance, targeting high Net Retention Rates (>105%) and strong EBITDA conversion.

By bridging the advisory gap, navigating complex regulatory transitions, and consolidating fragmented regional assets into pan-European platforms, mid-market private equity sponsors can generate superior returns and set the benchmark for European healthcare investing in 2026 and beyond.

Click here to read the report in full https://www.healthcare.digital/single-post/the-25m-to-250m-sweet-spot-why-europe-s-healthtech-mid-market-is-where-private-equity-returns-are